Retreatment with Cisplatin May Provide a Survival Advantage for Children with Relapsed/Refractory Hepatoblastoma: An Institutional Experience
There is no established standard salvage therapy regimen for relapsed hepatoblastoma
guidelineSophia Schermerhorn0:12 ↗
The Cincinnati Children's retrospective review of 30 patients represents one of the largest published cohorts evaluating patients with refractory or recurrent hepatoblastoma
epidemiologicalSophia Schermerhorn0:17 ↗
The overall survival for the cohort was about 50%
clinicalSophia Schermerhorn0:25 ↗
Children who received cisplatin as part of their salvage therapy had survival of about 80% compared to 25% for those who did not receive cisplatin
clinicalSophia Schermerhorn0:28 ↗
The improved survival outcomes with cisplatin may be due to persistent platinum sensitivity or better tumor biology rather than proving causality
opinionSophia Schermerhorn0:36 ↗
Most patients underwent additional surgery as part of their salvage therapy, either liver resection, liver transplant, or pulmonary metastasectomy
clinicalSophia Schermerhorn0:49 ↗
Salvage therapy for relapsed hepatoblastoma is multimodal
clinicalSophia Schermerhorn0:57 ↗
Cisplatin retreatment should be balanced with the risk of cumulative toxicity
opinionSophia Schermerhorn0:59 ↗
Indocyanine green is a sensitive adjunct in the identification and surgical management of local and metastatic hepatoblastoma
This is a single institution retrospective review of patients who received ICG prior to either pulmonary metastatectomy or liver resection for hepatoblastoma
clinicalSophia Schermerhorn0:12 ↗
ICG was highly sensitive for detecting hepatoblastoma, about 90%
clinicalSophia Schermerhorn0:22 ↗
In a meaningful number of cases, ICG was able to detect tumor deposits that were not visible, palpable, or detectable on preoperative imaging
clinicalSophia Schermerhorn0:27 ↗
Specificity was lower than sensitivity with false positives
clinicalSophia Schermerhorn0:39 ↗
False positives often represented vascular changes or inflammation
clinicalSophia Schermerhorn0:43 ↗
There were no adverse outcomes associated with any of the additional resections guided by ICG
clinicalSophia Schermerhorn0:46 ↗
ICG was effective in both open and minimally invasive surgery
clinicalSophia Schermerhorn0:50 ↗
ICG was effective in both relapse and primary disease
clinicalSophia Schermerhorn0:50 ↗
Quality of Life Outcomes for Patients Who Underwent Conventional Resection and Liver Transplantation for Locally Advanced Hepatoblastoma
This is a single institution cross-sectional study using validated pediatric quality of life surveys to evaluate long-term survivors of hepatoblastoma.
clinicalSophia Schermerhorn0:24 ↗
Survival for hepatoblastoma continues to improve.
epidemiologicalSophia Schermerhorn0:18 ↗
Long-term quality of life is becoming a more important outcome as hepatoblastoma survival improves.
opinionSophia Schermerhorn0:18 ↗
Overall quality of life outcomes were similar between liver transplant and resection groups for hepatoblastoma.
clinicalSophia Schermerhorn0:31 ↗
There was no significant difference in emotional, social, physical, or school functioning outcomes between transplant and resection groups.
clinicalSophia Schermerhorn0:31 ↗
Patients who underwent resection had lower overall procedure anxiety scores than transplant patients.
clinicalSophia Schermerhorn0:47 ↗
The finding of lower procedural anxiety in resection patients was mirrored in the parents' surveys.
clinicalSophia Schermerhorn0:53 ↗
Long-term quality of life outcomes appear comparable between patients who undergo resection and liver transplantation for hepatoblastoma.
clinicalSophia Schermerhorn0:55 ↗
Surgical strategy for hepatoblastoma can be focused on oncologic control given comparable quality of life outcomes.
opinionSophia Schermerhorn1:02 ↗
Characteristics of Transfusion and Association With Oncologic Outcomes in Hepatoblastoma Resection
It is not uncommon for a patient with hepatoblastoma to need a transfusion during resection
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:00 ↗
The study was multi-institutional and published in Pediatric Blood and Cancer in 2025
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:13 ↗
The study examined how intraoperative transfusion may affect recurrence and survival in hepatoblastoma resection patients
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:19 ↗
Of those transfused, the majority received red blood cells
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:25 ↗
Only 11% of transfused patients received platelets
Host summaryJill Knepprath summarizing a resource — not the host's own clinical position0:25 ↗